publications

Phase 1 and 2 Studies Demonstrate the Safety and Efficacy of Intraprostatic Injection of PRX302

May 14, 2012

by Sophiris Bio News Release

In: Posted Date, Publications, Published Date

Article published on November 24, 2011
Samuel Denmeade et al.

Background: PRX302 is a prostate specific antigen (PSA)–activated pore-forming protein toxin under development as a targeted approach for improving lowerurinary tract symptoms (LUTS) caused by

Read more

Sophiris wows Street with prostate cancer data

Jun 23, 2016

by Sophiris Bio News Release

In: Posted Date, Publications, Published Date

Article published on June 13, 2016
Michael Fitzhugh

Sophiris Bio Inc.’s shares (NASDAQ:SPHS) rose 69.2 percent to a $1.98 close on Friday after publishing data showing that a single injection of PRX302 (topsalysin) durably destroyed

Read more